Article
Do genetic polymorphisms modulate response rate and toxicity of Cisplatin associated with radiotherapy in laryngeal squamous cell carcinoma?: a case report.
Medicine - 1 Apr 2015
Lopes-Aguiar Leisa, Visacri Marília Berlofa, Nourani Carolina Marques Lopes, Costa Ericka Francislaine Dias, Nogueira Guilherme Augusto Silva, Lima Tathiane Regine Penna, Pincinato Eder Carvalho, Moriel Patrícia, Altemani João Maurício Carrasco, Lima Carmen Silvia Passos
Abstract excerpt
UNLABELLED: Cisplatin (CDDP) plus radiotherapy (RT) has been used to treat advanced laryngeal squamous cell carcinoma (LSCC) patients. Single nucleotide polymorphisms (SNPs) may be responsible for differences in chemo/radiosensitivity and side effects in those patients. We reported an advanced LSCC patient, who obtained durable complete response and unexpected pronounced toxicity during CDDP and RT, possibly due...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
